Abstract
AbstractAcquired drug resistance remains a major problem across oncogene-addicted cancers. Elucidation of mechanisms of resistance can inform rational treatment strategies for patients relapsing on targeted therapies while offering insights into tumor evolution. Here, we report acquired MET amplification as a resistance driver in a ROS1-rearranged lung adenocarcinoma after sequential treatment with ROS1 inhibitors. Subsequent combination therapy with lorlatinib plus capmatinib, a MET-selective inhibitor, induced intracranial and extracranial tumor response. At relapse, sequencing of the resistant tumor revealed a MET D1246N mutation and loss of MET amplification. We performed integrated molecular analyses of serial tumor and plasma samples, unveiling dynamic alterations in the ROS1 fusion driver and MET bypass axis at genomic and protein levels and the emergence of polyclonal resistance. This case illustrates the complexity of longitudinal tumor evolution with sequential targeted therapies, highlighting challenges embedded in the current precision oncology paradigm and the importance of developing approaches that prevent resistance.
Funder
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Publisher
Springer Science and Business Media LLC
Reference43 articles.
1. Gendarme, S., Bylicki, O., Chouaid, C. & Guisier, F. ROS-1 fusions in non-small-cell lung cancer: evidence to date. Curr. Oncol. 29, 641–658 (2022).
2. Lin, J. J. & Shaw, A. T. Recent advances in targeting ROS1 in lung cancer. J. Thorac. Oncol. 12, 1611–1625 (2017).
3. Davies, K. D. & Doebele, R. C. Molecular pathways: ROS1 fusion proteins in cancer. Clin. Cancer Res. 19, 4040–4045 (2013).
4. Shaw, A. T. et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann. Oncol. 30, 1121–1126 (2019).
5. Drilon, A. et al. Long-term efficacy and safety of entrectinib in ROS1 fusion-positive NSCLC. JTO Clin. Res. Rep. 3, 100332 (2022).
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献